Drug Search Results
More Filters [+]

RP-G28

Alternative Names: rp-g28, rpg28, rp g28
Latest Update: 2022-12-01
Latest Update Note: PubMed Publication

Product Description

An ultra-purified, high-concentration galacto-oligosaccharide, RP-G28, is being developed as a treatment for patients with LI.

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Qualigen
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for RP-G28

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Lactose Intolerance

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

G28-006

P3

Not yet recruiting

Lactose Intolerance

2019-05-01

Recent News Events